Advertisement

Disorders of Bile Acid Synthesis

  • P. T. Clayton

Abstract

Two defined inborn errors of metabolism affect the modifications of the cholesterol nucleus in the major pathway for bile acid synthesis: 3β-hydroxy-Δ5-C27-steroid-dehydrogenase (3β-dehydrogenase) deficiency and Δ4-3-oxo-steroid-5β-reductase (5β-reductase) deficiency. These disorders produce chronic cholestatic liver disease and malabsorption of fat and fat-soluble vitamins. Onset of symptoms is usually in the first year of life and, untreated, the liver disease can progress to cirrhosis. Treatment with chenodeoxycholic acid and cholic acid leads to dramatic improvement in the liver disease and the malabsorption.

Keywords

Bile Acid Cholic Acid Chenodeoxycholic Acid Bile Acid Synthesis Cholestatic Liver Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Björkhem I (1985) Mechanism of bile acid biosynthesis in mammalian liver. In: Danielsson H, Sjövall J (eds) Sterols and bile acids. New comprehensive biochemistry, vol 12. Elsevier, Amsterdam, pp 231–278CrossRefGoogle Scholar
  2. 2.
    Russell DW, Setchell KDR (1992) Bile acid biosynthesis. Biochemistry 31: 4737–4749PubMedCrossRefGoogle Scholar
  3. 3.
    Clayton PT (1991) Inborn errors of bile acid metabolism. J Inherited Metab Dis 14: 478–496PubMedCrossRefGoogle Scholar
  4. 4.
    Clayton PT, Leonard JV, Lawson AM, Setchell KDR, Anders-son S, Egestad B, Sjövall J (1987) Familial giant cell hepatitis associated with synthesis of 313,7a-dihydroxy-and 3ß,7a,12atrihydroxy-5-cholenoic acids. J Clin Invest 79: 1031–1038PubMedCrossRefGoogle Scholar
  5. 5.
    Horslen SP, Lawson AM, Malone M, Clayton PT (1992) 3(3Hydroxy-A5–C7-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology. J Inherited Metab Dis 15: 38–46Google Scholar
  6. 6.
    Jacquemin E, Setchell KDR, O’Connell NC, Estrada A, Maggiore G, Schmitz J, Hadchouel M, Bernard O (1994) A new cause of progressive intrahepatic cholestasis: 30-hydroxy-C,7-steroid dehydrogenase/isomerase deficiency. J Pediatr 125: 379–384PubMedCrossRefGoogle Scholar
  7. 7.
    Setchell KDR (1990) Disorders of bile acid synthesis. In: Walker WA, Durk PR, Hamilton JR, Walker-Smith JA, Watkins JB (eds) Pediatric gastrointestinal disease. Pathophysiology, diagnosis and management, vol 2. Dekker, Philadelphia, pp 922–1013Google Scholar
  8. 8.
    Ichimiya H, Egestad B, Nazer H, Baginski ES, Clayton PT, Sjövall J (1991) Bile acids and bile alcohols in a child with 30hydroxy-A5-C,7-steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment. J Lipid Res 32: 829–841PubMedGoogle Scholar
  9. 9.
    Lawson AM, Madigan MJ, Shortland DB, Clayton PT (1986) Rapid diagnosis of Zellweger syndrome and infantile Ref-sum’s disease by fast atom bombardment–mass spectrometry of urine bile salts. Clin Chim Acta 161: 221–231PubMedCrossRefGoogle Scholar
  10. 10.
    Mills K, Mushtaq I, Johnson A, Whitfield P, Clayton PT (1998) A method for the quantitation of conjugated bile acids in dried blood spots using electrospray ionization mass spectrometry. Pediatr Res 43: 361–368PubMedCrossRefGoogle Scholar
  11. 11.
    Buchmann MS, Kvittingen EA, Nazer H, Gunasekaran T, Clayton PT, Sjövall J (1990) Lack of 313-hydroxy-A5-C,7- steroid dehydrogenase/isomerase in fibroblasts from a child with urinary excretion of 3ß-hydroxy-A5-bile acids–a new inborn error of metabolism. J Clin Invest 86: 2034–2037PubMedCrossRefGoogle Scholar
  12. 12.
    Setchell KDR, Suchy FJ, Welsh MB, Zimmer-Nechemias L, Heubi J, Balistreri WF (1988) A4–3-Oxosteroid s13-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. J Clin Invest 82: 2148–2157PubMedCrossRefGoogle Scholar
  13. 13.
    Clayton PT, Patel E, Lawson AM, Carruthers RA, Tanner MS, Strandvik B, Egestad B, Sjövall J (1988) 3–0x0-A4 bile acids in liver disease. Lancet 1283–1284Google Scholar
  14. 14.
    Schneider BL, Setchell KDR, Whittington PF, Neilson KA, Suchy FJ (1994) A4–3-Oxosteroid 5(3-reductase deficiency causing neonatal liver failure and neonatal hemochromatosis. J Pediatr 124: 234–238CrossRefGoogle Scholar
  15. 15.
    Clayton PT (1994) A4–3-Oxosteroid 513-reductase deficiency and neonatal hemochromatosis (letter). J Pediatr 125: 845–846PubMedGoogle Scholar
  16. 16.
    Sumazaki R, Nakamura N, Shoda J, Kurosawa T, Tohma M (1997) Gene analysis in A4–3-oxosteroid 5(3-reductase deficiency. Lancet 349: 329PubMedCrossRefGoogle Scholar
  17. 17.
    Clayton PT, Mills KA, Johnson AW, Barabino A, Marazzi MG (1996) A4–3-Oxosteroid 5ß-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut 38: 623–628PubMedCrossRefGoogle Scholar
  18. 18.
    Balistreri WF (1991) Bile acid metabolism. J Inherit Metab Dis 14: 459–477PubMedCrossRefGoogle Scholar
  19. 19.
    Wevers RA, Cruysberg JRM, Van Heijst AFJ, Janssen-Ziljstra, Renier WO, Van Engelen BGM, Tolboom JJM (1992) Paediatric cerebrotendinous xanthomatosis. J Inherit Metab Dis 14: 374–376CrossRefGoogle Scholar
  20. 20.
    Kuriyama M, Fujiyama J, Yoshidome H, Takenaga S, Matsumoro K, Kasama T, Fukada K, Kuramoto T, Hoshita T, Seyama Y et al. (1991) Cerebrotendinous xanthomatosis: clinical features of eight patients and a review of the literature. J Neurol Sci 102: 225–232PubMedCrossRefGoogle Scholar
  21. 21.
    Bencze K, Polder DRV, Prockop LD (1990) Magnetic resonance imaging of the brain in CTX. J Neurol Neurosurg Psychiatry53: 166–167Google Scholar
  22. 22.
    Berginer VM, Shany S, Alkalay D, Berginer J, Dekel S, Salen G, Tint GS, Gazit D (1993) Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 42: 69–74PubMedCrossRefGoogle Scholar
  23. 23.
    Cali JJ, Russell DW (1991) Characterisation of human sterol 27-hydroxylase: a mitochondrial cytochrome P-45o that catalyses multiple oxidations in bile acid biosynthesis. J Biol Chem 266: 7774–7778PubMedGoogle Scholar
  24. 24.
    Babiker A, Andersson 0, Lund E, Xin RJ, Deeb S, Reshef A, Leitersdorf E, Diczfalusy U, Björkhem I (1997) Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem 272: 26253–26261PubMedCrossRefGoogle Scholar
  25. 25.
    Egestad B, Pettersson P, Skrede S, Sjövall J (1985) Fast atom bombardment mass spectrometry in the diagnosis of cerebrotendinous xanthomatosis. Scand J Clin Lab Invest 45: 443–446PubMedCrossRefGoogle Scholar
  26. 26.
    Koopman BJ, Molen JC, Wolthers BG, Waterreus RJ (1987) Screening for CTX by using an enzymatic method for 7ahydroxylated steroids in urine. Clin Chem 33: 142–143PubMedGoogle Scholar
  27. 27.
    Koopman BJ, Waterreus RJ, Brekel HWC, Wolthers BG (1986) Detection of carriers of CTX. Clin Chim Acta 158: 179–186PubMedCrossRefGoogle Scholar
  28. 28.
    Skrede S, Björkhem I, Kvittingen EA, Buchmann MS, East C, Grundy S (1986) Demonstration of 26-hydroxylation of C,7-steroids in human skin fibroblasts, and a deficiency of this activity in CTX. J Clin Invest 78: 729–735PubMedCrossRefGoogle Scholar
  29. 29.
    Berginer VM, Salen G, Shefer S (1984) Long-term treatment of. CTX with chenodeoxycholic acid therapy. N Engl J Med 311: 1649–1652PubMedCrossRefGoogle Scholar
  30. 30.
    Berginer VM, Berginer J, Korczyn AD, Tadmor R (1994) Magnetic resonance imaginng in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study. 36. J Neurol Sci 122: 102–108PubMedCrossRefGoogle Scholar
  31. 31.
    Lewis B, Mitchell WD, Marenah CB, Cortese C (1983) Cerebrotendinous xanthomatosis: biochemical response to inhibition of cholesterol synthesis. Br Med J 287: 21–22CrossRefGoogle Scholar
  32. 32.
    Mimura Y, Kuriyama M, Tokimura Y, Fujiyama J, Osame M, Takesako K, Tanaka N (1993) Treatment of cerebrotendinous xanthomatosis with low density lipoprotein ( LDL)-apheresis. J Neurol Sci 114: 227–230PubMedCrossRefGoogle Scholar
  33. 33.
    Chang WN, Lui CC (1997) Failure in the treatment of longstanding osteoporosis in cerebrotendinous xanthomatosis. J Formos Med Assoc 96: 225–227.PubMedGoogle Scholar
  34. 34.
    Cali JJ, Hsieh C-L, Francke U, Russell DW (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266: 7779–7783PubMedGoogle Scholar
  35. 35.
    Leitersdorf E, Reshef A, Meiner V, Levitzki R, Schwartz SP, Dann EJ, Berkman N, Cali JJ, Klapholz L, Berginer VM (1993) Frameshift and splice-junction mutations in the sterol 27hydroxylase gene cause cerebrotendinous xanthomatosis in Jews of Moroccan origin. J Clin Invest 91: 2488–2496PubMedCrossRefGoogle Scholar
  36. 36.
    Clayton PT, Casteels M, Mieli-Vergani G, Lawson AM (1995) Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis? Pediatr Res 37: 424–431PubMedCrossRefGoogle Scholar
  37. 37.
    Setchell KDR, Heubi JE, O’Connell NC, Hoffmann AF, Lavine JE (1997) Identification of a unique inborn error in bile and conjugation involving a deficiency in amidation. In: Paumgartner G, Stiehl A, Gerok W (eds) Bile acids in hepato biliary disease: basic and clinical applications. Kluwer Academic, Dordrecht, pp 43–47Google Scholar
  38. 38.
    Setchell KDR, Schwarz M, O’Connell NC, Lund EG, Davis DL, Lathe R, Thompson HR, Tyson RW, Sokol RJ, Russell DW (1998) Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7a-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 102: 1690–1703PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • P. T. Clayton

There are no affiliations available

Personalised recommendations